NCT00077558View on ClinicalTrials.gov

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
DRUG

fludarabine phosphate

DRUG

triapine

Trial Locations (4)

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

30342-4777

Blood and Marrow Transplant Group of Georgia, Atlanta

77030-4095

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00077558 - 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter